Cellectis CEO Provides Update on UCART Programs and ‘Laser Focus’ of Company in 2018
After a brief stumble with UCART123 that resulted in a clinical hold last year, Cellectis is moving on with its study.
Source: BioSpace
After a brief stumble with UCART123 that resulted in a clinical hold last year, Cellectis is moving on with its study.
Source: BioSpace